Mark E. Cooper
Impact in
- Nephrology top 0.5%
- Chronic Kidney Disease and Diabetes
- Renal Diseases and Glomerulopathies
-
- Renin-Angiotensin System Studies
- Blood Pressure and Hypertension Studies
Papers in
- Nephrology 11
- Chronic Kidney Disease and Diabetes 11
-
- Blood Pressure and Hypertension Studies 3
- Renin-Angiotensin System Studies 3
- Co-authors
- Dick de Zeeuw (2 shared papers)Barry Morton Brenner (2 shared papers)Ilkka Tikkanen (1 shared paper)R J Viskoper (1 shared paper)S Oren (1 shared paper)Carl Erik Mogensen (1 shared paper)Steen Neldam (1 shared paper)Terri J. Allen (3 shared papers)
In The Last Decade
Mark E. Cooper
17 papers receiving 2k citations
Mark E. Cooper's Hit Papers
Peers
Comparison fields: 5 of 72
- Nephrology 1.1k
- Cardiology and Cardiovascular Medicine 820
- Clinical Biochemistry 120
- Endocrinology, Diabetes and Metabolism 124
- Ophthalmology 52
Countries citing papers authored by Mark E. Cooper
This map shows the geographic impact of Mark E. Cooper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Cooper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Cooper more than expected).
Fields of papers citing papers by Mark E. Cooper
This network shows the impact of papers produced by Mark E. Cooper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Cooper. The network helps show where Mark E. Cooper may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark E. Cooper, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study Hit paper breakdown → | 2000 | 817 |
| 2 | 2002 | 428 | |
| 3 | 2001 | 220 | |
| 4 | 1998 | 189 | |
| 5 | 2000 | 91 | |
| 6 | 2006 | 79 | |
| 7 | 2004 | 71 | |
| 8 | 1999 | 54 | |
| 9 | 1992 | 47 | |
| 10 | 1988 | 45 | |
| 11 | 2008 | 39 | |
| 12 | 2005 | 37 | |
| 13 | 2003 | 24 | |
| 14 | 2013 | 18 | |
| 15 | 1989 | 9 | |
| 16 | 1997 | 5 | |
| 17 | 2000 | 1 | |
| 18 | Renoprotection with perindopril-indapamide below current recommended blood pressure targets in patients with type 2 diabetes mellitus: Results of the ADVANCE trial | 2008 | 1 |
About Mark E. Cooper
Mark E. Cooper is a scholar working on Nephrology, Cardiology and Cardiovascular Medicine, Clinical Biochemistry, Orthopedics and Sports Medicine and Hematology, having authored 18 papers that have together received 2.2k indexed citations. Recurring topics across this work include Chronic Kidney Disease and Diabetes (11 papers), Blood Pressure and Hypertension Studies (3 papers), Renin-Angiotensin System Studies (3 papers), Bone health and osteoporosis research (2 papers), Advanced Glycation End Products research (2 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (1 paper), Erythropoietin and Anemia Treatment (1 paper) and TGF-β signaling in diseases (1 paper). The work is most often cited by research in Nephrology (1.1k citations), Cardiology and Cardiovascular Medicine (820 citations), Clinical Biochemistry (120 citations), Endocrinology, Diabetes and Metabolism (124 citations) and Ophthalmology (52 citations). Mark E. Cooper has collaborated with scholars based in Australia, Denmark and Israel. Frequent co-authors include Dick de Zeeuw, Barry Morton Brenner, Ilkka Tikkanen, R J Viskoper, S Oren, Carl Erik Mogensen, Steen Neldam, Terri J. Allen, Fabrice Bonnet and Geoffrey Boner. Their work appears in journals such as Diabetologia, Journal of Hypertension, Diabetes & Metabolism, Current Eye Research and Diabetes.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.